The safety analysis indicated that there was no statistically significant difference in the occurrence of serious adverse events, including thrombotic events, between the treatment and control groups. Seventy percent of patients receiving TNFerade + SOC and 78% of those receiving SOC alone had at least one serious adverse event. Eleven patients (33%) receiving TNFerade with SOC and seven patients (39%) receiving SOC alone had a protocol-defined thrombotic event. Adverse events associated with TNFerade were Grade 1 and 2 flu-like symptoms.
"ASCO has been the first opportunity to share in detail the data emerging from the PACT study," stated Mark Thornton, M.D., M.P.H., Ph.D., GenVec's Senior Vice President of Product Development. "Pancreatic cancer has been one of the most challenging oncology indications for drug developers. We are enthused by both the current safety profile of TNFerade, and the preliminary survival data of this agent in the setting of locally advanced pancreatic cancer. We anticipate discussing potential trial modifications with the FDA, and remain focused on advancing the PACT Study as expediently as possible," added Dr. Thornton.
The presented poster is available on the Company's website at www.genvec.com . To view the poster, click on the Investor Relations page, then follow the link to Webcasts and Data.
GenVec, Inc. is a biopharmaceutical company developing novel
gene-based therapeutic drugs and vaccines. Each of the Company's
product candidates uses patent-protected technology to deliver
genes that produce beneficial proteins. GenVec's lead product,